A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2007
This article has no abstract
Epistemonikos ID: 76c4ade45b025a2c02155ae7633ed00d4a8efbfc
First added on: Apr 16, 2025